CDK2 and breast cancer: In the first study, the thiazolo[3,2-a]benzimidazole moiety was conjugated with different isatin motifs (138, Figure 19) to afford new CDK2 inhibitors (IC50: 26.24 ± 1.4–96.46 ± 5.3 nM) with potent activity against BC MCF-7 cell line (IC50: 1.27 ± 0.06–16.83 ± 0.95 μM) and against MDA-MB-231 cell line (IC50: 2.60 ± 1.47–20.90 ± 1.17 μM) [120].